News >

Dual Biomarker Signature Holds Predictive Promise for Response to Anti-PD-L1 Therapy in NSCLC

Lisa Miller
Published: Wednesday, Nov 16, 2016

Sonja Althammer, PhD

Sonja Althammer, PhD

Recent research suggests that the presence of PD-L1–positive and CD8+ cells may be useful for predicting responses in patients with non-small cell lung cancer (NSCLC) who have been treated with durvalumab (MEDI4736).

“These are very encouraging results for us, however, we need to keep in mind that this is preliminary data and that it is important to confirm this analysis on an independent dataset,” Althammer said. In an interview, Althammer expressed that, with AstraZeneca, the manufacturer of the drug, researchers are looking to identify further trials for a confirmation study.

References

  1. Althammer S, Steele K, Rebelatto M, et al. Combinational CD8+ and PD-L1+ cell densities correlate with response and improved survival in non-small cell lung cancer (NSCLC) patients treated with durvalumab. Presented at: 2016 SITC Annual Meeting; November 9-13, 2016; National Harbor, MD. Abstract O1.
  2. Rizvi NA, Brahmer JR, Ou S-HI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 33, 2015 (suppl; abstr 8032).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Publication Bottom Border
Border Publication
x